Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Kronos Bio, Inc. (KRON) reported a Q3 loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a $0.26 loss. This is an improvement from the $0.54 loss per share reported a year ago.
November 13, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio reported a Q3 loss of $0.23 per share, better than the expected $0.26 loss, showing improvement from last year's $0.54 loss per share.
Kronos Bio's reported loss per share was better than expected, indicating better financial performance than anticipated. This positive surprise is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100